p53 Polymorphism and Human Papillomavirus Infection in Hong Kong Women with Cervical Cancer

2000 ◽  
Vol 50 (1) ◽  
pp. 60-63 ◽  
Author(s):  
Y.F. Wong ◽  
T.K.H. Chung ◽  
T.H. Cheung ◽  
T. Nobori ◽  
G.M. Hampton ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Hong Kong ◽  
Human Papillomavirus ◽  
Human Papillomavirus Infection ◽  
Papillomavirus Infection ◽  
P53 Polymorphism

Epidemiology of Human Papillomavirus Infection and Cervical Cancer and Future Perspectives in Hong Kong, Singapore and Taiwan

Vaccine ◽  
2008 ◽  
Vol 26 ◽  
pp. M60-M70 ◽  
Author(s):  
Sun Kuie Tay ◽  
Hextan Y.S. Ngan ◽  
Tang-Yuan Chu ◽  
Annie N.Y. Cheung ◽  
Eng Hseon Tay
Keyword(s):  
Cervical Cancer ◽  
Hong Kong ◽  
Human Papillomavirus ◽  
Future Perspectives ◽  
Human Papillomavirus Infection ◽  
Papillomavirus Infection

Human Papillomavirus Infection of the Cervix

2021 ◽  
pp. 170-174
Author(s):  
Jacqueline M. Mills ◽  
Elizabeth A. Stier
Keyword(s):  
Cervical Cancer ◽  
At Risk ◽  
Human Papillomavirus ◽  
Hpv Vaccine ◽  
Cervical Neoplasia ◽  
Hpv 16 ◽  
Human Papillomavirus Infection ◽  
Papillomavirus Infection ◽  
Hpv Genotypes ◽  
Prophylactic Hpv Vaccine

In 1992 Lorincz et al. were the first to evaluate the clinicopathologic correlation with 11 recently identified human papillomavirus (HPV) genotypes: 31, 33, 35, 42, 43, 44, 45, 51, 52, 56, and 58. Using cervical samples from 8 studies that included specimens from 2627 women, HPV genotypes were categorized by the likelihood of association with grades of cervical neoplasia (from normal to cancer). These findings were the basis of the determination that (a) HPV causes cervical cancer, (b) detection of the cancer associated HPV genotypes could identify women at risk for cervical pre-cancer and cancer, and (c) a prophylactic HPV vaccine should include protection against (at least) HPV 16 and 18.

Sign in / Sign up

Export Citation Format

Share Document